Bristol-Myers Squibb

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. 

CEO
Christopher S. Boerner
CEOChristopher S. Boerner
Employees
32,500
Employees32,500
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1933
Founded1933
Employees
32,500
Employees32,500

BMY Key Statistics

Market cap
123.53B
Market cap123.53B
Price-Earnings ratio
17.53
Price-Earnings ratio17.53
Dividend yield
4.11%
Dividend yield4.11%
Average volume
16.73M
Average volume16.73M
High today
$61.13
High today$61.13
Low today
$59.92
Low today$59.92
Open price
$60.19
Open price$60.19
Volume
12.80M
Volume12.80M
52 Week high
$62.89
52 Week high$62.89
52 Week low
$42.52
52 Week low$42.52

Stock Snapshot

With a market cap of 123.53B, Bristol-Myers Squibb(BMY) trades at $60.90. The stock has a price-to-earnings ratio of 17.53 and currently yields dividends of 4.1%.

As of 2026-04-01, Bristol-Myers Squibb(BMY) stock has fluctuated between $59.92 and $61.13. The current price stands at $60.90, placing the stock +1.6% above today's low and -0.4% off the high.

The Bristol-Myers Squibb(BMY)'s current trading volume is 12.8M, compared to an average daily volume of 16.73M.

During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $62.89 at its peak.

During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $62.89 at its peak.

BMY News

Simply Wall St 20h
Is Bristol Myers Squibb Price Near US$60 Supported By Cash Flow And Earnings Models

Wondering if Bristol-Myers Squibb at around US$59.73 is a bargain or a value trap? This article walks through the key signals that matter for you as a sharehold...

Is Bristol Myers Squibb Price Near US$60 Supported By Cash Flow And Earnings Models
Simply Wall St 3d
A Look At Bristol Myers Squibb Valuation As Growth Portfolio Outperforms Recent GAAP Loss

Advertisement Why Bristol-Myers Squibb (BMY) is on investors’ radar Bristol-Myers Squibb (BMY) is drawing attention after recent share price moves, with the s...

A Look At Bristol Myers Squibb Valuation As Growth Portfolio Outperforms Recent GAAP Loss
TipRanks 5d
Bristol-Myers Squibb’s Repotrectinib DDI Study: What Investors Should Watch

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. The Phase 1 study “Phase 1, 2-Cohort, Open-label, Fixed-sequence, Drug-...

Analyst ratings

59%

of 32 ratings
Buy
37.5%
Hold
59.4%
Sell
3.1%

More BMY News

TipRanks 5d
Milvexian Phase 3 Wraps Up: What Bristol-Myers Squibb Investors Should Watch Next

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. The Phase 3 study “A Phase 3, Randomized, Double-blind, Placebo-control...

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.